Litigation Details for The California Institute of Technology v. Broadcom Limited (C.D. Cal. 2016)

The California Institute of Technology v. Broadcom Limited (C.D. Cal. 2016)

Docket		Date Filed	2016-05-26
Court	District Court, C.D. California	Date Terminated	2023-11-22
Cause	35:271 Patent Infringement	Assigned To	George H. Wu
Jury Demand	Both	Referred To	Alicia G. Rosenberg
Patents	9,555,001
Link to Docket	External link to docket

Details for The California Institute of Technology v. Broadcom Limited (C.D. Cal. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-05-26				External link to document

California Institute of Technology v. Broadcom Limited, 2:16-cv-03714: Litigation Summary and Patent Analysis

Last updated: August 2, 2026

California Institute of Technology v. Broadcom Limited concerned three Caltech patents covering low-density parity-check, or LDPC, error-correcting codes used in Wi-Fi chipsets. Caltech accused Broadcom of direct infringement and Apple of using and selling products containing infringing Broadcom chips. A jury awarded approximately $1.1 billion, including about $837.8 million against Apple and $270.2 million against Broadcom. The Federal Circuit affirmed the core infringement and validity findings in 2022. The litigation later ended through settlement and dismissal, with financial terms not publicly disclosed. [1][2]

What patents protected Caltech’s LDPC technology in the Broadcom litigation?

The asserted patent estate consisted primarily of three U.S. patents directed to coding techniques used to improve the reliability and efficiency of wireless data transmission.

Patent	Subject matter	Litigation status	Approximate patent-term position
U.S. Patent No. 7,116,710	Irregular repeat-accumulate codes and related decoding systems	Asserted at trial	Expired in or around 2022
U.S. Patent No. 7,421,032	Encoded data transmission using LDPC-type codes	Asserted at trial	Expired in or around 2022
U.S. Patent No. 8,284,833	Further coding and decoding implementations	Asserted at trial	Expired in or around 2022

The patents originated from Caltech research on error-correcting codes. The technology was relevant to IEEE 802.11n and 802.11ac wireless standards and appeared in Broadcom Wi-Fi semiconductor products incorporated into Apple devices.

The Federal Circuit’s published decision identified U.S. Patent Nos. 7,116,710, 7,421,032, and 8,284,833 as the patents at issue on appeal. [1]

What technology did the Caltech patents cover?

LDPC codes add structured redundancy to transmitted data. A receiving device uses that redundancy to detect and correct errors caused by noise, interference, or signal degradation.

The asserted claims focused on technical features such as:

• The structure of parity-check matrices.
• The relationship between information bits and parity bits.
• Repeat-accumulate coding.
• Encoding and decoding operations.
• Efficient implementation in wireless communication hardware.

The case did not involve a pharmaceutical product, biologic, active ingredient, medical method, or drug-delivery system. Its commercial value arose from the incorporation of patented coding techniques into wireless chipsets and consumer electronics.

What was the procedural history of Caltech v. Broadcom?

Caltech filed the action in the U.S. District Court for the Central District of California in 2016 under case number 2:16-cv-03714. Apple was later involved as a defendant because its products incorporated Broadcom chips accused of practicing the patented technology.

Key litigation timeline

Date	Event
2016	Caltech filed suit against Broadcom in the Central District of California
2017-2019	Claim construction, discovery, expert proceedings, and dispositive motions
January 2020	Jury trial concluded with liability findings against Apple and Broadcom
January 2020	Jury awarded approximately $1.1 billion in damages
2020	District court entered judgment and addressed post-trial motions
2021	Apple and Broadcom appealed to the Federal Circuit
February 2022	Federal Circuit affirmed the principal infringement and validity rulings
2022-2023	Further appellate activity, including petitions to the U.S. Supreme Court
2023	Supreme Court denied review
2023 onward	Remaining disputes ended through settlement and dismissal

The case was one of the largest U.S. patent verdicts involving wireless semiconductor technology. The verdict rested on a reasonable-royalty theory based on sales of accused products and the commercial value attributed to the patented coding features.

How much did Apple and Broadcom owe Caltech?

The jury’s damages award totaled approximately $1.1 billion:

Defendant	Approximate award
Apple	$837.8 million
Broadcom	$270.2 million
Total	Approximately $1.1 billion

The damages theory covered Apple products containing accused Broadcom chips. Caltech argued that Broadcom’s chips practiced the patented LDPC technology and that Apple’s use and sale of products containing those chips supported liability.

The award was based on a reasonable royalty rather than lost profits. The parties disputed the appropriate royalty base, comparable licenses, the contribution of the patented technology to the accused products, and whether the asserted claims covered the relevant chip implementations.

The Federal Circuit did not overturn the central jury findings that the asserted claims were infringed and not invalid. Its decision preserved the principal judgment against Apple and Broadcom, subject to the issues addressed in the appellate opinion. [1]

What did the Federal Circuit decide in Caltech v. Broadcom?

The Federal Circuit’s decision in Caltech v. Broadcom Ltd., 25 F.4th 976 (Fed. Cir. 2022), addressed infringement, validity, claim construction, damages, and several evidentiary issues.

The court held that substantial evidence supported the jury’s infringement findings. The court also rejected the principal challenges to the asserted patents’ validity.

Infringement findings

The accused Broadcom chips were found to implement the claimed coding methods. Apple products using those chips were implicated through Apple’s product sales and use of the accused technology.

The appellate record involved both direct infringement theories against Broadcom and liability theories concerning Apple’s products. The Federal Circuit’s analysis focused on whether the evidence supported the jury’s determination that the accused chip architectures and operations met the claim limitations.

Validity findings

Apple and Broadcom challenged the patents under anticipation and obviousness theories. The Federal Circuit upheld the relevant jury findings rejecting those challenges.

The validity disputes involved prior-art references concerning LDPC coding and whether a skilled person would have combined or modified those references to reach the claimed structures and methods. The Federal Circuit gave substantial weight to the trial record, including expert testimony and the jury’s resolution of factual disputes.

Damages and evidentiary issues

The parties disputed how the reasonable royalty should be calculated and what evidence could be considered in determining the value of the patented technology.

The Federal Circuit’s decision preserved the central verdict while addressing specific legal and evidentiary issues. The case did not produce a broad rule eliminating component-based damages for semiconductor patents. Its effect was more fact-specific and depended on the evidence concerning the role of LDPC functionality in the accused chips and end products.

Was there a Paragraph IV challenge in this case?

No. Paragraph IV litigation was not applicable.

Paragraph IV certifications arise under the Hatch-Waxman Act when a generic-drug applicant challenges a listed patent in an Abbreviated New Drug Application. Caltech v. Broadcom involved wireless communication patents, semiconductor chips, and consumer electronics. It did not involve an ANDA, an NDA, a generic drug, or FDA Orange Book certification.

The defendants’ invalidity challenges were litigated under the Patent Act through district-court defenses and Federal Circuit appeals, not through a Paragraph IV notice letter.

What was the Orange Book status of the Caltech patents?

The Caltech patents were not Orange Book-listed patents.

The FDA Orange Book covers patents associated with approved prescription drug products. The patents in this case covered wireless coding and decoding technology, not drug substances, formulations, methods of treatment, or drug-delivery systems. There was no FDA regulatory exclusivity period associated with the asserted patents.

Regulatory issue	Status
FDA-approved drug	Not involved
Orange Book listing	None
Paragraph IV certification	None
Hatch-Waxman litigation	None
Biologic or biosimilar pathway	Not involved
Regulatory exclusivity	Not applicable

When did the Caltech patents lose exclusivity?

The asserted patents reached the end of their ordinary U.S. patent terms in or around 2022. Their expiration removed the principal forward-looking risk of an injunction against continued use of the patented LDPC technology.

The litigation still had economic significance after expiration because Caltech could pursue damages for past infringement. Patent expiration does not eliminate accrued damages claims for conduct occurring during the enforceable term.

The case therefore shifted from an injunction and future-sales dispute to a historical damages and appellate dispute. The later settlement resolved the remaining litigation without establishing a public post-expiration royalty framework.

Did the case create a biosimilar or generic-entry risk?

No. The case created no biosimilar or pharmaceutical generic-entry risk.

The relevant commercial risk was semiconductor and device litigation risk. A company selling Wi-Fi chips or products using those chips could face exposure if it practiced valid, enforceable claims during the patent term. After expiration, the main risks were damages for historical sales, litigation costs, indemnification obligations, and possible supply-chain disruption.

What patent litigation affected Apple and Broadcom’s Wi-Fi products?

Caltech’s action was directed at Broadcom’s wireless chips and Apple products incorporating those chips. The dispute raised several supply-chain questions:

1. Whether Broadcom or Apple controlled the relevant technical implementation.
2. Whether Broadcom’s chip-level activities and Apple’s product-level activities created separate damages exposure.
3. Whether Apple could obtain indemnification from Broadcom.
4. Whether alternative chips could be substituted without redesign or certification work.
5. Whether the accused coding functions were essential to the products or were merely one component of a broader Wi-Fi implementation.

The verdict demonstrated that patent exposure can extend across the semiconductor supply chain. A chip supplier may face direct liability while an original equipment manufacturer faces separate exposure based on its own sales and use of products incorporating the chip.

How strong was Caltech’s patent estate?

Caltech’s estate was strong in litigation but limited in remaining duration.

Factors supporting strength

• A jury found infringement after a full trial.
• The asserted claims survived validity challenges.
• The Federal Circuit affirmed the core infringement and validity findings.
• The patents covered implementation-level technology used in industry-standard wireless products.
• The accused products had substantial commercial volume.
• The defendants included major technology companies with significant sales and litigation resources.

Factors limiting long-term value

• The asserted patents expired in or around 2022.
• The patents were technology-specific rather than broad platform patents.
• The commercial value depended on implementation in Wi-Fi chipsets.
• A future case would require proof that a later-generation product practiced the specific claim limitations.
• The patents did not create regulatory exclusivity or control access to a drug market.

The estate was therefore commercially valuable for historical damages and licensing leverage but had limited post-expiration blocking power.

Which companies challenged Caltech’s patent position?

Apple and Broadcom were the principal defendants and appellate challengers. Their defenses included noninfringement, anticipation, obviousness, claim-construction arguments, and challenges to the damages methodology.

The case did not produce a broad industry invalidation of Caltech’s LDPC patent portfolio. It addressed the asserted claims and accused implementations in the record.

Other wireless and semiconductor companies, including Qualcomm, Intel, MediaTek, and Samsung, operate in overlapping technology markets, but they were not defendants in this action based on the cited case record.

Was the case settled, and what were the settlement terms?

The litigation ultimately ended through settlement and dismissal. Public reporting did not disclose the settlement amount or detailed licensing terms.

The settlement is commercially important because it avoided continued proceedings over a large damages award and eliminated the need for a further public determination of damages after the patents had reached expiration. It also limited public visibility into:

• The final amount paid by Apple and Broadcom.
• Any allocation of payment between the companies.
• Whether the parties exchanged broader patent licenses.
• Whether the agreement included releases covering related Caltech patents.
• Whether indemnification or contribution obligations were resolved privately.

No publicly reported settlement established a continuing royalty obligation for future use of the expired patents.

What generic launch scenarios existed?

There was no generic launch scenario in the Hatch-Waxman sense. The relevant technology-entry scenarios were:

Scenario	Commercial consequence
Settlement before final judgment	Continued product supply with negotiated financial payment
Injunction during the patent term	Potential chip redesign, supplier substitution, or product disruption
Damages-only resolution	Continued sales with historical infringement payment
Patent expiration	Removal of future infringement liability for the expired claims
Invalidity judgment	Elimination of liability for the challenged claims
Noninfringing redesign	Reduced exposure but possible engineering and certification costs

The settlement and patent expiration made a future injunction or royalty on the asserted patents unlikely.

What manufacturing and intellectual-property barriers were involved?

The primary barrier was implementation knowledge rather than physical manufacturing capacity.

A competing chip supplier would need to determine whether its encoder and decoder architecture practiced the asserted claims. A redesign could require changes to:

• Parity-check matrix construction.
• Code rates.
• Decoder architecture.
• Memory allocation.
• Throughput and latency characteristics.
• IEEE 802.11 compliance testing.
• Power consumption and silicon area.

Because wireless chipsets are highly integrated, replacing one coding implementation can affect verification, firmware, interoperability, and customer qualification. Those practical barriers can create commercial leverage even when the patent claims cover only one technical subsystem.

How does this case compare with pharmaceutical patent litigation?

Issue	Caltech v. Broadcom	Pharmaceutical patent litigation
Technology	Wireless coding and semiconductor hardware	Drug substances, formulations, methods, biologics
FDA involvement	None	NDA, ANDA, BLA, or 351(k) pathways
Orange Book	Not applicable	Often central
Paragraph IV	Not applicable	Common generic challenge mechanism
Biosimilar risk	None	Relevant for biologics
Damages basis	Chip and device sales	Drug sales and market entry
Exclusivity	Patent term only	Patent term plus regulatory exclusivity
Product substitution	Chip redesign or supplier change	Generic or biosimilar substitution
Main commercial risk	Supply-chain and historical damages	Launch timing, price erosion, and market-share loss

The case should not be analyzed using drug-patent concepts such as Orange Book listing, pediatric exclusivity, new chemical entity exclusivity, or biosimilar interchangeability.

What is the current business significance of the case?

The case remains relevant for companies evaluating patent exposure in standardized technologies and component supply chains.

Its main lessons are:

• Patent risk can attach to a chip supplier and the device manufacturer using the chip.
• Standard-essential or standards-related technology can generate large damages even without a formal injunction.
• A patent portfolio can have high litigation value near expiration if accused sales are large.
• Component-level proof does not automatically eliminate end-product damages exposure.
• Settlement value may remain substantial after patent expiration because past damages and litigation costs persist.
• Public verdict amounts may materially exceed the confidential settlement value.

Key Takeaways

• Caltech asserted U.S. Patent Nos. 7,116,710, 7,421,032, and 8,284,833 against Broadcom and Apple.
• The patents covered LDPC error-correcting technology used in Wi-Fi chipsets.
• A jury awarded approximately $1.1 billion, including about $837.8 million against Apple and $270.2 million against Broadcom.
• The Federal Circuit affirmed the core infringement and validity findings in 2022.
• The patents expired in or around 2022, eliminating future blocking rights under the asserted claims.
• The case involved no FDA approval, Orange Book listing, Paragraph IV certification, generic drug, or biosimilar.
• The litigation later ended through settlement and dismissal, with financial terms undisclosed.
• The principal commercial precedent concerns semiconductor supply-chain liability, standard-related technology, damages, and patent expiration.

FAQs

Did Caltech hold standard-essential patents against Broadcom?

The patents concerned technology used in Wi-Fi implementations, but the case was litigated as a patent infringement action rather than as a conventional FRAND dispute involving a declared standard-essential patent portfolio.

Could Broadcom continue selling the accused chips after the Caltech patents expired?

Expiration removed infringement liability for future use of the expired claims. Broadcom could still face liability for pre-expiration sales and conduct, subject to the settlement and any applicable releases.

Did Apple manufacture the accused LDPC chips?

The accused chips were associated with Broadcom. Apple was sued because its products incorporated and sold products containing the accused technology, creating separate product-level exposure.

Did the Caltech verdict affect Qualcomm or MediaTek?

The verdict did not impose liability on Qualcomm or MediaTek. Its broader effect was industry signaling: suppliers of wireless chipsets faced potential exposure when their implementations practiced patent claims used in standardized products.

Were the Caltech patents eligible for patent-term extension?

No pharmaceutical patent-term extension or regulatory-based exclusivity applied. The patents were directed to wireless communication technology and were governed by ordinary U.S. patent-term rules.

References

1. California Institute of Technology v. Broadcom Ltd., 25 F.4th 976 (Fed. Cir. 2022).

2. California Institute of Technology v. Broadcom Limited, No. 2:16-cv-03714, U.S. District Court for the Central District of California, docket materials.

3. United States Patent and Trademark Office. (2024). Patent term adjustment and patent term calculation guidance. https://www.uspto.gov

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-filesablytyped